Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Why the Australian Pharmaceutical Industries (ASX:API) share price is going nuts

The Australian Pharmaceutical Industries (ASX:API) share price is going bananas after receiving a takeover offer from Wesfarmers (ASX:WES).

The Australian Pharmaceutical Industries Ltd (ASX: API) share price is going bananas after receiving a takeover offer from Wesfarmers Ltd (ASX: WES).

The takeover bid from Wesfarmers for API

API announced this morning that it has received a takeover offer from Wesfarmers at an offer price of $1.38 per share, representing a premium of 20.5% to API’s closing share price on 9 April 2021.

Wesfarmers told API that it has entered into an agreement with API’s largest shareholder, Washington H. Soul Pattinson and Co. Ltd (ASX: SOL), which holds a 19.3% stake.

The API board has commenced an assessment of the proposal.

API said: “The API Board notes that its portfolio of pharmacy distribution, health and beauty retail and skin care businesses have attractive characteristics and are well positioned for growth in Priceline Pharmacy’s leading digital offering, and growth in the performance of its Clear Skincare business as a result of the recent investment in its clinic network. The indicative proposal has been made at a time where COVID-19 restrictions have resulted in store and clinic closures and these have significantly impacted on API’s operational performance.”

The API board is now assessing whether the offer is reflective of the long-term growth prospects of API and the expected short-term impacts of the pandemic-related lockdown restrictions.

The company advised shareholders not to take any action in relation to this indicative proposal.

Business update

API also announced today that it’s going to cease manufacturing personal care and over-the-counter products in New Zealand and outsource their manufacturing and focus on pharmacy distribution and retail businesses.

The company advised that current and recent lockdowns during June and July caused the temporary closure of 72% of the non-pharmacy company-owned Priceline stores and 75% of the Clear Skincare clinic network.

Management said that prior to the latest lockdowns, it was expecting full year underlying EBIT (EBIT explained) would be around $75 million. Clear Skincare was recording double digit sales growth, positive like for like sales growth in the majority of Priceline Pharmacy stores, growth in register margins and basket sizes and steadily improving like for like sales in CBD stores.

But, due to the lockdowns, it’s now expecting full year underlying EBIT to be in the range of $66 million to $68 million. Reported EBIT is expected to be in the range of $31 million to $33 million. The lockdowns are impacting EBIT at approximately $1 million per week.

The difference in underlying and reported relates to ending the New Zealand manufacturing, the costs of closing nine Priceline stores based on changes to customer foot traffic and ongoing profitability.

The new Marsden Park distribution centre in Sydney remains on time and within budget, It is anticipated this will deliver a 20% improvement in cost per unit with annualised savings of around $8 million of EBITDA.

Summary thoughts on the API share price

This seems like a solid offer for API from Wesfarmers, if I were a shareholder I’d be inclined to take the money and put it into businesses with longer-term growth prospects.

ASX growth shares could be one area to look at.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz owns shares of WHSP.
Skip to content